The Soccer Club Barcelona also ‘fishes’ in Brazilian football and is done with Yan Couto (Curitiba, June 3, 2002), right side of Coritibaas reported Balloon support. The 17-year-old pearl will arrive in Barcelona in June, at the time she reaches the age of majority. The operation would have closed at 5 million euros more variables and reinforces a position that neither Semedo nor Sergi Roberto have managed to endorse. The culé set is ahead of other teams, such as Bayer Leverkusen and Arsenal, which also intended to be done with one of the most promising players of the moment. In fact, in October of last year he was included in the list of the 60 best young people in the world by The guardian.The lateral side, measures 1.68m, arrives with the U-17 world champion vitola, tournament in which he was one of the most prominent of the verdeamarelha. Headline in all matches in which he was available, his performance had a mole in the form of expulsion in the second meeting of the first phase, which would miss the next two clashes. However, I would return in quarters to eleven and it would be decisive both in the semifinal against France (3-2), and in the final against Mexico, with two assists. Curiously, that last pass would be converted by Lázaro Vinicius in the final two to one, player who has declared his love for Real Madrid in a recent interview with ACE.
Reviewed by James Ives, M.Psych. (Editor)Sep 24 2018Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Gilenya® (fingolimod) for the treatment of children and adolescents 10 to 17 years of age with relapsing remitting forms of multiple sclerosis (RRMS). If approved, Gilenya® is expected to be the first oral disease-modifying therapy indicated for these patients based on a randomized controlled clinical study. The younger patient population experiences two-to-three times as many relapses as adults, often leading to a more severe prognosis and earlier disability compared to adult-onset MS. If approved, Gilenya would address the urgent need faced by these young people. This market authorization would expand the age range of Gilenya, one of the most prescribed MS treatments worldwide. Gilenya was previously approved for adults with RRMS aged 18 years and older in Europe.”The lives of kids are immensely impacted by the early onset of MS, from playing sports, going to school or enjoying time with friends and family. We need to address the urgent need for new and effective treatments, and with Gilenya, we may now have an option that can make a substantial difference for young patients”, said Paul Hudson, Chief Executive Officer, Novartis Pharmaceuticals. “This CHMP positive opinion is a testament to our relentless dedication to reimagining MS care across all generations. We are very excited to be a step closer to bringing this much-needed treatment to young MS patients across Europe.”Related StoriesNew curriculum to improve soft skills in schools boosts children’s health and behaviorPuzzling paralysis affecting healthy children warns CDCResearch team receives federal grant to study obesity in children with spina bifida”Today’s CHMP positive opinion is a momentous advancement for the children and adolescents impacted by MS,” said Pedro Carrascal, President, European Multiple Sclerosis Platform. “Young European patients and their families, who have long been hoping for an effective disease modifying therapy, could soon have a new treatment option to alleviate the devastating impact of this condition.”The CHMP positive opinion is based on the PARADIGMS trial, a first-of-its-kind clinical study in MS specifically designed for children and adolescents aged 10 to 17 years. Results from the double-blind, randomized, multi-center Phase III study of Gilenya vs. interferon beta-1a show that compared to interferon beta-1a, Gilenya significantly reduced the annualized relapse rates by 82% (relative difference to interferon beta-1a, p<0.001) and delayed the time to first relapse. Furthermore, it also significantly reduced the number of new or newly enlarged T2 lesions up to 24 months by 53% (p<0.001) and the annualized rate of brain volume loss (brain shrinkage) by 40%. The full PARADIGMS data was recently published in The New England Journal of Medicine.The European Commission will review the CHMP opinion and is expected to deliver its final decision within three months. The decision will be applicable to all 28 European Union member states plus Iceland, Norway and Liechtenstein. Gilenya received FDA approval for the treatment of children and adolescents 10 years of age and older with MS on May 11, 2018. Source:https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-gilenya-treatment-children-and-adolescents-ms-marking-major-medical-advance-young-ms-patients-europe